72 completed, 17 terminated, 12 unknown, 9 recruiting. 124 Phase 2, 16 Phase 1, 13 Phase 3.
Follow Hydrocortisone: new trials by email Literature Review of Hydrocortisone trials Research Report on Hydrocortisone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Osilodrostat (Isturisa), Placebo, hydrocortisone 10mg - Mild Autonomous Cortisol Secretion (MACS), Diabetes Mellitus (Type 2) | Phase 2 | Not yet recruiting | Beckey Trinh | 44 | 2026-11-01 | 2026-11-06 |
| Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder Yohimbine + Hydrocortisone, Active rTMS, Placebo - Opioid Use Disorder | Phase 2 | Not yet recruiting | Wayne State University | 20 | 2026-10-01 | 2025-12-30 |
| Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma Therapeutic Hydrocortisone, Cytarabine, Dexamethasone - Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Vanderbilt-Ingram Cancer Center | 59 | 2026-09-25 | 2026-10-02 |
| Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML." Revumenib, Fludarabine, Cytarabine (Ara-C) - Leukemia, Myeloid, Acute | Phase 2 | Not yet recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 24 | 2026-08-31 | 2026-07-22 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial Tocilizumab, Baricitinib, Anakinra - Sepsis | Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 2000 | 2026-07-09 | 2026-10-20 |
| Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL) Asciminib Adult formulation, Asciminib Pediatric formulation, Dexamethasone - Acute Lymphoblastic Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Phase 1 / Phase 2 | Recruiting | Novartis Pharmaceuticals | 50 | 2026-07-05 | 2026-11-12 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome Biospecimen Collection, Cytarabine, Lumbar Puncture - Hematopoietic and Lymphatic System Neoplasm | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 26 | 2025-06-04 | 2026-11-10 |
| Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma Dexamethasone, Vincristine, Inotuzumab - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 128 | 2025-01-23 | 2026-07-16 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 100 | 2024-12-27 | 2026-08-10 |
| A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome Methylprednisolone, Dexamethasone, Hydrocortisone - Acute Respiratory Distress Syndrome | Phase 2 / Phase 3 | Completed | Fayoum University | 195 | 2024-08-01 | 2026-09-01 |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat Anti-CD123 ADC IMGN632, Bone Marrow Aspiration and Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Children's Oncology Group | 2023-08-01 | 2023-09-01 | |
| Early Versus Conventional Cessation of Hydrocortisone in Septic Shock normal saline solution, Hydrocortisone and normal saline solution - Septic Shock, Adverse Event | Phase 2 | Unknown | Mahidol University | 160 | 2023-07-05 | 2024-04-05 |
| Using rTMS to Explore Neural Mechanisms of Stress-Induced Opioid Use Placebo oral tablet, Yohimbine + Hydrocortisone, sham rTMS - Stress, Opioid-use Disorder | Phase 2 | Withdrawn | Wayne State University | 2023-04-10 | 2023-04-13 | |
| rTMS of Limbic Circuitry in Stress Modulation in Healthy Volunteers yohimbine + hydrocortisone, medial prefrontal cortex rTMS, Placebo oral tablet - Stress, Healthy | Phase 2 | Withdrawn | Wayne State University | 2023-04-10 | 2023-04-13 | |
| Androgen Reduction in Congenital Adrenal Hyperplasia Abiraterone acetate, Placebo, Hydrocortisone - Congenital Adrenal Hyperplasia | Phase 2 | Withdrawn | University of Texas Southwestern Medical Center | 2023-01-01 | 2023-02-01 | |
| A Comparative Clinical Trial Evaluating the Effect and Safety of Tacrolimus Versus Hydrocortisone Tacrolimus ointment, Hydrocortisone 1% cream - Dermatologic Disease | Phase 2 | Completed | Tanta University | 100 | 2022-11-28 | 2026-10-30 |
| Corticosteroid Intralesional Injection as an Alternative Treatment in Oral Pyogenic Granuloma in the Esthetic Zone. Solu-Cortef - Oral Pyogenic Granuloma | Phase 2 / Phase 3 | Unknown | Beni-Suef University | 30 | 2022-05-01 | 2022-09-14 |
Showing 20 of 124. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (23) · Leukemia (14) · Burkitt Lymphoma (13) · Prostatic Neoplasms (11) · Leukemia, Biphenotypic, Acute (7) · Lymphoma (7) · Sepsis (7) · Addison Disease (6) · Adrenal Hyperplasia, Congenital (6) · Lymphoma, Large B-Cell, Diffuse (6) · Shock, Septic (6) · Adrenal Insufficiency (5) · Leukemia, Myeloid, Acute (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma, Mantle-Cell (3)
National Cancer Institute (NCI) (10) · Children's Oncology Group (8) · St. Jude Children's Research Hospital (6) · Haukeland University Hospital (5) · Beth Israel Deaconess Medical Center (4) · Dana-Farber Cancer Institute (4) · Stanford University (4) · Wayne State University (3) · Asan Medical Center (2) · Soroka University Medical Center (2) · Therapeutic Advances in Childhood Leukemia Consortium (2) · University of California, San Francisco (2) · University of Texas Southwestern Medical Center (2) · AIDS Malignancy Consortium (1) · Academic and Community Cancer Research United (1)
United States (77) · Canada (16) · Australia (11) · Puerto Rico (7) · France (5) · Norway (5) · Switzerland (5) · Israel (4) · Egypt (3) · Germany (3) · South Korea (3) · Brazil (2) · Finland (2) · Japan (2) · New Zealand (2)
Michael W Donnino, MD (2) · Sima Jeha, MD (2) · Wen-Kai Weng (2) · Adham Mohamed, PharmD (1) · Adrian Corneliu Iancu, M.D, Ph.D (1) · Allan G Coates, DO (1) · Allen Yeoh, MBBS (1) · Aminah Jatoi (1) · Andrew Wolf, MBBChir MD (1) · Anna G Nilsson, MD, PhD (1) · Ariela Noy, MD (1) · Barb Melosky, MD (1) · Barbara Pro, MD (1) · Barton Kamen, MD (1)
PMID 41671463, PMID 35622074, PMID 38767196, PMID 10722036, PMID 1138591, PMID 11502226, PMID 11600602, PMID 12011123, PMID 12454520, PMID 12545007, PMID 12700374, PMID 15042678, PMID 1607900, PMID 16556894, PMID 16570523, PMID 16809737, PMID 17136402, PMID 18353115, PMID 19064966, PMID 19638218, PMID 19648788, PMID 20332511, PMID 20646908, PMID 20871859, PMID 21427372, PMID 22210879, PMID 22488662, PMID 22563089, PMID 227054, PMID 22777514, PMID 22835045, PMID 23140612, PMID 23450051, PMID 23525934, PMID 23672956, PMID 24484547, PMID 24838355, PMID 25667107, PMID 25957391, PMID 26218852, PMID 26376074, PMID 26527777, PMID 26573073, PMID 26771781, PMID 26903338, PMID 27038920, PMID 27162802, PMID 27429037, PMID 27680873, PMID 27695824
U10CA180886 (7), U10CA098543 (6), N01CM00071 (2), P30CA014599 (2), 2009 (1), 2025 (1), K23NS048152 (1), N01CM00038 (1), N01CM00099 (1), N01CM62201 (1), N01CM62204 (1), N01CM62209 (1), P01CA049605 (1), P30CA006516 (1), P30CA006973 (1)